Cargando…

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability

OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstappen, M, van Mulligen, E, de Jong, P H P, van der Helm-Van Mil, A H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299506/
https://www.ncbi.nlm.nih.gov/pubmed/32393523
http://dx.doi.org/10.1136/rmdopen-2020-001220
_version_ 1783547401919791104
author Verstappen, M
van Mulligen, E
de Jong, P H P
van der Helm-Van Mil, A H M
author_facet Verstappen, M
van Mulligen, E
de Jong, P H P
van der Helm-Van Mil, A H M
author_sort Verstappen, M
collection PubMed
description OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determine the prevalence and sustainability of DFR and evaluated potential predictors for DFR. METHODS: A systematic literature search was performed in March 2019 in multiple databases. All clinical trials and observational studies reporting on discontinuation of DMARDs in RA patients in remission were included. Our quality assessment included a general assessment and assessment of the description of DFR. Prevalence of DFR and its sustainability and flares during tapering and after DMARD stop were summarised. Also, potential predictors for achieving DFR were reviewed. RESULTS: From 631 articles, 51 were included, comprising 14 clinical trials and 5 observational studies. DFR definition differed, especially for the duration of DMARD-free state. Considering only high- and moderate-quality studies, DFR was achieved in 5.0%–24.3% and sustained DFR (duration>12 months) in 11.6%–19.4% (both relative to the number of patients eligible for tapering). Flares occurred frequently during DMARD tapering (41.8%–75.0%) and in the first year after achieving DFR (10.4%–11.8%), while late flares, >1 year after DMARD-stop, were infrequent (0.3%–3.5%). Many patient characteristics lacked association with DFR. Absence of autoantibodies and shared epitope alleles increased the chance of achieving DFR. CONCLUSIONS: DFR is achievable in RA and is sustainable in ~10%–20% of patients. DFR can become an important outcome measure for clinical trials and requires consistency in the definition. Considering the high rate of flares in the first year after DMARD stop, a DMARD-free follow-up of >12 months is advisable to evaluate sustainability.
format Online
Article
Text
id pubmed-7299506
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72995062020-06-22 DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability Verstappen, M van Mulligen, E de Jong, P H P van der Helm-Van Mil, A H M RMD Open Rheumatoid Arthritis OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determine the prevalence and sustainability of DFR and evaluated potential predictors for DFR. METHODS: A systematic literature search was performed in March 2019 in multiple databases. All clinical trials and observational studies reporting on discontinuation of DMARDs in RA patients in remission were included. Our quality assessment included a general assessment and assessment of the description of DFR. Prevalence of DFR and its sustainability and flares during tapering and after DMARD stop were summarised. Also, potential predictors for achieving DFR were reviewed. RESULTS: From 631 articles, 51 were included, comprising 14 clinical trials and 5 observational studies. DFR definition differed, especially for the duration of DMARD-free state. Considering only high- and moderate-quality studies, DFR was achieved in 5.0%–24.3% and sustained DFR (duration>12 months) in 11.6%–19.4% (both relative to the number of patients eligible for tapering). Flares occurred frequently during DMARD tapering (41.8%–75.0%) and in the first year after achieving DFR (10.4%–11.8%), while late flares, >1 year after DMARD-stop, were infrequent (0.3%–3.5%). Many patient characteristics lacked association with DFR. Absence of autoantibodies and shared epitope alleles increased the chance of achieving DFR. CONCLUSIONS: DFR is achievable in RA and is sustainable in ~10%–20% of patients. DFR can become an important outcome measure for clinical trials and requires consistency in the definition. Considering the high rate of flares in the first year after DMARD stop, a DMARD-free follow-up of >12 months is advisable to evaluate sustainability. BMJ Publishing Group 2020-05-07 /pmc/articles/PMC7299506/ /pubmed/32393523 http://dx.doi.org/10.1136/rmdopen-2020-001220 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Rheumatoid Arthritis
Verstappen, M
van Mulligen, E
de Jong, P H P
van der Helm-Van Mil, A H M
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
title DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
title_full DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
title_fullStr DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
title_full_unstemmed DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
title_short DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
title_sort dmard-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299506/
https://www.ncbi.nlm.nih.gov/pubmed/32393523
http://dx.doi.org/10.1136/rmdopen-2020-001220
work_keys_str_mv AT verstappenm dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability
AT vanmulligene dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability
AT dejongphp dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability
AT vanderhelmvanmilahm dmardfreeremissionasnoveltreatmenttargetinrheumatoidarthritisasystematicliteraturereviewofachievabilityandsustainability